Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
FMR LLC reports beneficial ownership of 8,059,903.11 shares of Veracyte Inc. common stock, representing 10.1% of the class. The filing (Schedule 13G/A, Amendment No. 5) lists sole dispositive power for 8,059,903.11 shares and no shared voting power. The report names Abigail P. Johnson in the cover responses.
Veracyte EVP and General Counsel Annie McGuire reported recent share transactions in Veracyte, Inc. common stock. On June 4, 2026, she completed open-market sales of 3,176 shares in total, consisting of 1,776 shares at a weighted average price of $50.1168 per share and 1,400 shares at a weighted average price of $49.3061 per share. These sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025. Following these sales, she directly held 137,240 shares of Veracyte common stock. On June 2, 2026, 3,292 shares were withheld at $47.80 per share to satisfy tax withholding obligations upon vesting of restricted stock units, which the company notes did not represent a market sale.
VERACYTE, INC. executive Jonathan Wygant, VP and Chief Accounting Officer, reported a tax-related share disposition in company stock. On June 2, 2026, 1,361 shares of common stock were withheld to satisfy his tax withholding obligations tied to the vesting of restricted stock units and did not represent a sale. Following this withholding, he directly holds 44,073 shares of Veracyte common stock.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported recent transactions in the company’s common stock. On June 4, 2026, she executed two open-market sales totaling 3,561 shares at weighted average prices of $49.2836 and $50.0913 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2025.
Separately, on June 2, 2026, 3,693 shares were withheld to cover tax obligations upon the vesting of restricted stock units; this was not an open-market sale. After these transactions, Chambers directly holds 173,280 shares of Veracyte common stock.
VERACYTE, INC. Chief Scientific & Medical Officer Phillip G. Febbo reported a routine share disposition tied to equity compensation. On June 2, 2026, 3,730 shares of common stock were withheld at $47.80 per share to cover tax withholding obligations from vesting restricted stock units, and the company notes this does not represent a market sale. Following this tax withholding event, Febbo directly holds 149,797 shares of common stock.
Veracyte, Inc. chief executive Marc Stapley reported an exercise-and-sale transaction in company stock. On June 4, 2026 he exercised stock options covering 138,051 shares of common stock at $36.60 per share and sold the same 138,051 shares in open-market trades at a weighted average price of $50.1234 per share pursuant to a Rule 10b5-1 plan.
The filing shows 9,012 shares of common stock were withheld on June 2, 2026 to cover tax obligations tied to vesting restricted stock units, which the company notes does not represent a sale. Following these transactions, Stapley directly owns 440,494 shares of Veracyte common stock.
VERACYTE, INC. Global Chief Commercial Officer John Leite reported an open-market sale of 13,975 shares of common stock on June 4, 2026 at a weighted average price of about $50.07 per share, executed under a pre-arranged Rule 10b5-1 plan. On June 2, 2026, 4,059 shares were withheld to satisfy tax obligations from vesting restricted stock units, which was not a market sale. Following these transactions, Leite directly holds 132,305 shares of Veracyte common stock.
VCYT related filing reports an intended resale of common stock by an issuer representative and recent 10b5-1 sales by an individual. The filing lists 3176 shares of Common stock described as Restricted Stock Units with an offering date of 06/02/2026. It also records a 10b5-1 sale of 10,204 shares on 05/06/2026 generating $398,211.10.